Enantiopure Indolizinoindolones with in vitro Activity against Blood‐ and Liver‐Stage Malaria Parasites. Issue 12 (3rd November 2015)

• Record Type: Journal Article
• Authors: Pereira, Nuno A. L.; Monteiro, Ângelo; Machado, Marta; Gut, Jiri; Molins, Elies; Perry, M. Jesus; Dourado, Jorge; Moreira, Rui; Rosenthal, Philip J.; Prudêncio, Miguel; Santos, Maria M. M.
• Is Part Of: ChemMedChem. Volume 10:Issue 12(2015:Dec.)
• Page Start: 2080
• Page End: 2089
• Publication Date: 2015-11-03
• Subjects: diastereoselectivity -- drug design -- dual-stage antimalarials -- malaria -- nitrogen heterocycles; Pharmaceutical chemistry -- Periodicals; 615.19005
• DOI: 10.1002/cmdc.201500429
• Languages: English
• ISSNs: 1860-7179

Abstract

Abstract: Malaria continues to be a major cause of morbidity and mortality to this day, and resistance to drugs like chloroquine has led to an urgent need to discover novel chemical entities aimed at new targets. Here, we report the discovery of a novel class of potential antimalarial compounds containing an indolizinoindolone scaffold. These novel enantiopure indolizinoindolones were synthesized, in good‐to‐excellent yields and excellent diastereoselectivities, by cyclocondensation reaction of ( S )‐ or ( R )‐tryptophanol and 2‐acyl benzoic acids, followed by intramolecular α‐amidoalkylation. Interestingly, we were able to synthesize for the first time 7, 13b‐ cis indolizinoindolones in a two‐step route. The novel compounds showed promising activity against erythrocytic stages of the human malaria parasite, Plasmodium falciparum, and liver stages of the rodent parasite Plasmodium berghei . In particular, an ( S )‐tryptophanol‐derived isoindolinone was identified as a promising starting scaffold to search for novel antimalarials, combining excellent activity against both stages of the parasite′s life cycle with low cytotoxicity and excellent metabolic and chemical stability in vitro. Abstract : All about antimalarials : A novel class of potential antimalarial compounds containing an indolizinoindolone scaffold showed promising activity against erythrocytic stages of the human malaria parasite, Plasmodium falciparum, and liver stages of the rodent parasite Plasmodium berghei . The most promising compound exhibited IC50 values of 1.2 and 0.6 μm for the erythrocytic and liver stages, respectively, with excellent metabolic and chemical stability.